EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Develco Pharma.

    Client Virtual Booth

    DEVELCO PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Develco Pharma
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hohenrainstrasse 12 D CH-4133 Pratteln
    Telephone
    Telephone
    +41 61 425 50 20
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.develco.ch/?page_id=3300&lang=en
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression

    Details:

    KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resistant depression.


    Lead Product(s): Ketamine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: KET01

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: HMNC Brain Health

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 14, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Dep...

    Details:

    KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resistant depression.


    Lead Product(s): Ketamine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Ketabon

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: HMNC Brain Health

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 28, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    aspen-api-m-2024-08-19

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search